J&J forms 'innovation centres' in global biotech hubs to access emerging tech
This article was originally published in Scrip
Johnson & Johnson's new regional "innovation centres" will expand on the company's success with the US Janssen Labs project that opened earlier this year in San Diego to assist life science startups and connect the pharmaceutical company to promising new therapeutics, medical devices and consumer healthcare products (scripintelligence.com, 20 January 2012).
You may also be interested in...
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Richard Mason, head of Johnson & Johnson Innovation, London (EMEA), talks to Scrip senior writer, Lucie Ellis, about why R&D innovation hubs are still necessary to boost new scientific developments in the healthcare sector.
Big pharma investments in early innovation are paying off in ways that still are hard to measure in any concrete way, but green shoots are sprouting through the pavement as startups supported by multimillion-dollar initiatives evolve from concept to reality.